Skip to main content
. Author manuscript; available in PMC: 2015 Feb 6.
Published in final edited form as: Sci Transl Med. 2014 Aug 6;6(248):248ra105. doi: 10.1126/scitranslmed.3009246

Fig. 2. In vitro inhibition of ADP-induced platelet aggregation and disaggregation by APT102 in platelet-rich plasma from a healthy human volunteer.

Fig. 2

(A) Dose response of ADP added to platelet-rich plasma (at arrow). (B) Inhibition of 5 µM ADP–induced platelet aggregation by APT101 (25 µg/ml) and its optimized derivative, APT102 (6.5 and 25 µg/ml), added before ADP. (C) APT102 (2.5 µg/ml), adenosine (20 µM), or AMP (20 µM) was added at the “inhibitor” arrow 6 min after maximal aggregation. Only APT102 completely reversed aggregation. (D) Adenosine dose dependently (1, 10, and 100 µM) but only partially reversed platelet aggregation. Blood was collected in tubes containing heparin to maintain physiologic calcium concentration. Results shown are representative of triplicate assays. Similar results were obtained in two other healthy volunteers.